- Citations, last 5 years
- 224
- Works, last 5 years
- 16
- h-index
- 24
- Scientists listed
- 1
- Grants since 2016
- 3
Grants received
2024–2025 · research · R44
IND-enabling safety and toxicity testing of a subcutaneous formulation of the PTP1B inhibitor MSI-1436, a novel strategy for treating fatal cardiomyopathy in Duchenne muscular dystrophy patients
Kevin Strange · Ovid Therapeutics (United States) · funded by National Institutes of Health
2017–2019 · research · R44
Development of the PTP1B inhibitor MSI-1436 for therapeutic stimulation of heart regeneration following acute myocardial infarction
Viravuth P Yin · Ovid Therapeutics (United States) · funded by National Institutes of Health
2017–2021 · research · R44
Development of the PTP1B inhibitor MSI-1436 for therapeutic stimulation of heart regeneration following acute myocardial infarction
Viravuth P Yin · Ovid Therapeutics (United States) · funded by National Institutes of Health